Last week in a late breaking session at Transcatheter Cardiovascular Therapeutics (TCT) 2011, OrbusNeich presented data for the company’s first-of-its-kind Combo Dual Therapy Stent, which combines a drug elution with the pro-healing healing GenousTM technology.
While the current standard of care for patients with coronary artery disease, drug eluting stents (DES), have reduced the risk of restenosis (narrowing of the artery), even the most advanced DES can cause delayed healing. The Combo Dual Therapy Stent is the first dual therapy stent to offer the best of both worlds, a stent combining pro-healing technology with a drug elution.
Data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bioEngineered stEnt) trial demonstrated the safety and efficacy of the dual therapy stent (DTS) compared to a clinically proven DES. The primary end point of the study was in-stent late lumen loss at nine months, which is the difference in diameter of the stented area before and after the procedure.
Russo Partners was on-site in San Francisco to support and maximize awareness of OrbusNeich’s data announcement in the medical community. Our efforts included securing and coordinating in-person media interviews as well as the use of social media, utilizing Twitter to alert followers to OrbusNeich’s news releases and presentations.
We are excited by this promising data and the potential benefits it has for patients, and we are looking forward to additional data announcements from OrbusNeich when we can continue to provide guidance as well as support for their communications activities.
Below are examples of coverage generated from the data announcement: